GRPR and neoplasm: In orthotopic tumor tissues, 111In-JMV4168 bound with 2.2 ± 4% of added dose (%AD), whereas low binding was observed in the blocking group with 0.1% AD, confirming the specific binding of 111In-JMV4168 to GRPR ex vivo (Dalm et al., 2015).